William G. Hawkins
Expertise in
46
conditions

Dr. William G. Hawkins

General Surgery
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
Accepting New Patients
Offers Telehealth
Expertise in
46
conditions
University Medical Associates Of The Medical University Of South Carol
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Hawkins is a General Surgeon in Charleston, South Carolina. Dr. Hawkins is highly rated in 46 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Hawkins is currently accepting new patients.

His clinical research consists of co-authoring 188 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
General Surgery
Licenses
Surgery in MO
Hospital Affiliations
Musc Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

UNIVERSITY MEDICAL ASSOCIATES OF THE MEDICAL UNIVERSITY OF SOUTH CAROL
171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Device, Drug
Study Drug: Cu-64 DOTA-ECLi
Study Phase: Phase 1
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Procedure
Study Drugs: BMS-813160, Nivolumab, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: Optimized Neoantigen Synthetic Long Peptide Vaccine, Poly-ICLC
Study Phase: Phase 1
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Evaluation of the Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
Enrollment Status: Terminated
Publish Date: May 06, 2025
Intervention Type: Drug
Study Drug: Pantoprazole
Study Phase: Phase 2
Pre-operative Adaptive Short Course Radiation Therapy in Gastric Cancer
Pre-operative Adaptive Short Course Radiation Therapy in Gastric Cancer
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Drug, Procedure
Study Drugs: CDX-301, CDX-1140
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: July 17, 2024
Intervention Type: Drug, Biological, Procedure
Study Drugs: Poly-ICLC, CD4/CD8-Positive Personalized Neoantigen Peptide Vaccine
Study Phase: Phase 1
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Enrollment Status: Terminated
Publish Date: October 10, 2023
Intervention Type: Biological, Procedure, Device
Study Drug: Personalized Neoantigen DNA Vaccine
Study Phase: Phase 1
The Effect of Preoperative and Postoperative Incentive Spirometry in Patients Undergoing Major Abdominal Surgery
The Effect of Preoperative and Postoperative Incentive Spirometry in Patients Undergoing Major Abdominal Surgery
Enrollment Status: Terminated
Publish Date: May 17, 2023
Intervention Type: Device
Study Phase: Not Applicable
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Enrollment Status: Completed
Publish Date: February 14, 2023
Intervention Type: Device, Drug
Study Drug: Dapagliflozin
Study Phase: Phase 1
Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery
Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery
Enrollment Status: Terminated
Publish Date: December 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 10, 2022
Intervention Type: Drug
Study Phase: Phase 1
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Enrollment Status: Terminated
Publish Date: April 12, 2022
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery
Enrollment Status: Terminated
Publish Date: April 12, 2022
Intervention Type: Other
Study Phase: Not Applicable
Evaluation of Fluorescence Imaging in Hepatobiliary Surgery
Evaluation of Fluorescence Imaging in Hepatobiliary Surgery
Enrollment Status: Withdrawn
Publish Date: January 24, 2022
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Enrollment Status: Withdrawn
Publish Date: December 09, 2021
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2
Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement
Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement
Enrollment Status: Terminated
Publish Date: May 15, 2020
Intervention Type: Other
Study Phase: Not Applicable
Epidural Analgesia Use in Pancreatic Resections
Epidural Analgesia Use in Pancreatic Resections
Enrollment Status: Completed
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 19, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study
Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study
Enrollment Status: Completed
Publish Date: January 22, 2019
Intervention Type: Procedure
Thunderbeat™ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Registry Trial
Thunderbeat™ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Registry Trial
Enrollment Status: Terminated
Publish Date: September 19, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 21 Less Clinical Trials

188 Total Publications

Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.
Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.
Journal: Science immunology
Published: August 15, 2025
Similar Doctors
Expertise in
11
conditions
Dr. David B. Adams
General Surgery
Expertise in
11
conditions
Dr. David B. Adams
General Surgery
171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Adams is a General Surgeon in Charleston, South Carolina. Dr. Adams is highly rated in 11 conditions, according to our data. His top areas of expertise are Chronic Pancreatitis, Hereditary Pancreatitis, Gastroparesis, Pancreatectomy, and Islet Cell Transplantation. Dr. Adams is currently accepting new patients.

Expertise in
17
conditions
Dr. Denise Carneiro
General Surgery
Expertise in
17
conditions
Dr. Denise Carneiro
General Surgery

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Denise Carneiro is a General Surgeon in Charleston, South Carolina. Dr. Carneiro is highly rated in 17 conditions, according to our data. Her top areas of expertise are Hyperparathyroidism, Thyroid Cancer, Parathyroid Hyperplasia, Parathyroidectomy, and Thyroidectomy.

Prabhakar K. Baliga
Expertise in
5
conditions
Dr. Prabhakar K. Baliga
General Surgery
Expertise in
5
conditions
Dr. Prabhakar K. Baliga
General Surgery

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Prabhakar Baliga is a General Surgeon in Charleston, South Carolina. Dr. Baliga has been practicing medicine for over 43 years is highly rated in 5 conditions, according to our data. His top areas of expertise are Polycystic Kidney Disease, End-Stage Renal Disease (ESRD), Obesity, Kidney Transplant, and Liver Transplant. Dr. Baliga is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hawkins's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 34 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile